Recombinant RabMAb® Antibodies

Overview of RabMAb (Recombinant) Antibodies

Recombinant technology combined with RabMAb® antibodies produced in rabbits have resulted in an industry-leading range of primary monoclonal rabbit antibodies.

​The motive behind engineering RabMAb rabbit monoclonal antibodies in recombinant form is to increase the sensitivity to very high levels while not compromising on the consistency. There are many advantages of such a combination.

Recombinant RabMAb Antibody

At present, there are more than 10 000 recombinant RabMAb antibodies as well as Abcam’s custom RabMAb development service.

Table 1. The benefits of recombinant antibodies and RabMAb antibodies

RabMAb rabbit monoclonal antibodies Recombinant antibodies
Low background High consistency and reproducibility
High specificity Improved sensitivity
High affinity (10-12kD possible) Improved specificity
Diverse epitope recognition Animal-free production

However, recombinant antibodies have more to offer than just their addition to RabMAb antibodies; these benefits include:

To see the full range of recombinant RabMAb antibodies, click here.

About Abcam

Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.

Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 6, 2019 at 11:41 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Abcam. (2019, June 06). Recombinant RabMAb® Antibodies. News-Medical. Retrieved on July 15, 2019 from https://www.news-medical.net/whitepaper/20190606/Recombinant-RabMAb-Antibodies.aspx.

  • MLA

    Abcam. "Recombinant RabMAb® Antibodies". News-Medical. 15 July 2019. <https://www.news-medical.net/whitepaper/20190606/Recombinant-RabMAb-Antibodies.aspx>.

  • Chicago

    Abcam. "Recombinant RabMAb® Antibodies". News-Medical. https://www.news-medical.net/whitepaper/20190606/Recombinant-RabMAb-Antibodies.aspx. (accessed July 15, 2019).

  • Harvard

    Abcam. 2019. Recombinant RabMAb® Antibodies. News-Medical, viewed 15 July 2019, https://www.news-medical.net/whitepaper/20190606/Recombinant-RabMAb-Antibodies.aspx.

Other White Papers by this Supplier